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Introduction
Human cytomegalovirus (CMV) received its name from its 
  capacity to induce two characteristic and successive cytopathic 
effects. The early cytopathic effect (ECE) consists of the round-
ing of infected fi  broblasts, whereas the late cytopathic effect 
(LCE) is characterized by the appearance of granular or dense 
intracytoplasmic and intranuclear inclusion bodies, as well 
as by an increased cell volume (Gandhi and Khanna, 2004; 
  Sekhon et al., 2004). The molecular mechanisms accounting for 
these cytopathic effects are elusive.
CMV is an opportunistic pathogen that establishes life-
long latent infection without overt clinical disease in immuno-
competent individuals, but can cause severe illness in utero, in 
neonates, and in patients with acquired or iatrogenic immuno-
defi  ciency. CMV infection can be associated with colitis (Tzankov 
et al., 2003), retinitis (Chiou et al., 2002), and encephalitis 
(DeBiasi et al., 2002) accompanied by local cell deaths.
CMV encodes two antiapoptotic proteins, especially the 
viral mitochondria–localized inhibitor of apoptosis (vMIA; 
pUL37 × 1; Goldmacher et al., 1999). vMIA protects CMV-
  infected cells from apoptosis in the late phase of the viral life 
cycle (Reboredo et al., 2004), and thus, vMIA-defi  cient CMV 
cannot replicate (because it kills the infected cells) unless it in-
fects cells that overexpress Bcl-2–like apoptosis inhibitors such 
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eplication of human cytomegalovirus (CMV) re-
quires the expression of the viral mitochondria–
  localized inhibitor of apoptosis (vMIA). vMIA inhibits 
apoptosis by recruiting Bax to mitochondria, resulting in 
its neutralization. We show that vMIA decreases cell size, 
reduces actin polymerization, and induces cell rounding. 
As compared with vMIA-expressing CMV, vMIA-deﬁ  cient 
CMV, which replicates in ﬁ  broblasts expressing the ade-
noviral apoptosis suppressor E1B19K, induces less cyto-
pathic effects. These vMIA effects can be separated from 
its cell death–inhibitory function because vMIA modulates 
cellular morphology in Bax-deﬁ  cient cells. Expression of 
vMIA coincided with a reduction in the cellular adenosine 
triphosphate (ATP) level. vMIA selectively inhibited one 
component of the ATP synthasome, namely, the mitochon-
drial phosphate carrier. Exposure of cells to inhibitors of 
oxidative phosphorylation produced similar effects, such 
as an ATP level reduced by 30%, smaller cell size, and de-
ﬁ  cient actin polymerization. Similarly, knockdown of the 
phosphate carrier reduced cell size. Our data suggest that 
the cytopathic effect of CMV can be explained by vMIA 
effects on mitochondrial bioenergetics.
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as E1B19K (Reboredo et al., 2004). Although there is some 
functional similarity between Bcl-2 and vMIA, which both 
  inhibit apoptosis-associated mitochondrial outer membrane 
  per  meabilization (MOMP), there is no obvious sequence similarity 
between the two proteins (Goldmacher et al., 1999; Boya et al., 
2001, 2004; Hayajneh et al., 2001; Goldmacher, 2005). Moreover, 
in contrast to Bcl-2, vMIA induces the fragmentation of the tubu-
lar mitochondrial network, reducing its connectivity (McCormick 
et al., 2003; Perfettini et al., 2005). The vMIA protein is largely 
confi  ned to the mitochondrial compartment, and it coimmuno-
precipitates with the adenine nucleotide translocase (ANT; 
Goldmacher et al., 1999; Vieira et al., 2001), which is the anti-
porter responsible for the exchange of ADP and ATP at the inner 
mitochondrial membrane (for review see Palmieri, 2004). In 
  addition, vMIA has been shown to physically interact with the 
protein Bax, recruiting it to mitochondria while neutralizing its 
proapoptotic function (Poncet et al., 2004). Because vMIA 
loses its antiapoptotic action in Bax-defi  cient cells (Arnoult 
et al., 2004), it appears that vMIA exerts its antiapoptotic func-
tion solely by neutralizing Bax.
Based on these premises, we decided to evaluate the con-
tribution of vMIA to CMV-induced cytopathic effects. We re-
port that vMIA mediates the ECEs and LCEs of CMV infection 
through a novel effect on mitochondrial bioenergetics that is 
  independent from its antiapoptotic function.
Results
Effects of vMIA on mitochondrial 
morphology, cell size, actin cytoskeleton, 
and cellular dynamics
Mitochondria of two stable cell lines constitutively expressing 
vMIA, i.e., a human cervical carcinoma cell line (HeLa) and an 
immortalized mouse fi  broblast cell line (NIH3T3), look rounder 
and smaller than control mitochondria (Fig. 1 A). They present 
a highly disturbed organization, with mitochondrial fragmenta-
tion, matrix swelling, and reduction of the number of cristae 
(Fig. 1 B). This phenotype is not associated with a reduction 
of global mitochondrial mass, as determined by staining of the 
mitochondria with the potential-independent dye MitoTracker 
green (Fig. 1 C). Moreover, the abundance of proteins from the 
respiratory chain was not altered by vMIA (Fig. 1 D). We ob-
served a reduction in the size of vMIA-expressing cells. This 
  applied to both the cellular volume (Fig. 2 A) and the cytoplas-
mic membrane surface (Fig. 2 B) as measured by fl  ow cytom-
etry, as well as to the mean contact surface area of adherent cells 
(Fig. 2 C). There was no difference in the cell cycle distribu-
tion between vector-only and vMIA-transfected HeLa cells 
(Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200604069/DC1), and the difference in size between vMIA-
expressing and control cells was found in both the G1 and the 
G2/M phases of the cell cycle (Fig. S1 B). vMIA-expressing 
cells showed an altered actin cytoskeleton with fewer stress 
 fi bers and poorly polymerized cortical actin (Fig. 2 D). vMIA-
expressing NIH3T3 cells exhibited a signifi  cant delay in their 
adherence compared with vector-only–transfected control cells 
(Fig. 2 E). Moreover, vMIA-expressing NIH3T3 cells were less 
effi  cient in “wound healing” in vitro, meaning that they migrated 
less rapidly into a cell-free area of the culture substratum, which 
was generated by scratching the monolayer (Fig. 2 F). Similarly, 
vMIA-expressing HeLa cells exhibited a reduced motility, as 
determined by videomicroscopy (unpublished data).
Apoptosis-unrelated morphological 
effects of vMIA
The effects of vMIA on cellular morphology appear to be inde-
pendent from its impact on apoptosis regulation, as indicated by 
two independent lines of evidence. As compared with Neo cells, 
HeLa cells expressing vMIA were resistant against a panel of 
apoptosis inducers, including CD95 ligand, the lysosomal toxin 
ciprofl  oxacin (Boya et al., 2003), and anoikis. In contrast, vMIA 
had no apoptosis-inhibitory effects in NIH3T3 cells (Fig. S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200604069/DC1). 
Thus, the vMIA effects on NIH3T3 cell morphology must be in-
dependent from its apoptosis-regulatory function. Accordingly, 
the siRNA-mediated knockdown of Bax, which is the target 
of vMIA-mediated apoptosis modulation (Arnoult et al., 2004; 
  Poncet et al., 2004), did not reduce the size difference between 
Neo and vMIA-transfected HeLa cells (Fig. 3 A). siRNA-mediated 
knockdown of the Bax homologue Bak, which does not interact 
with vMIA (Arnoult et al., 2004), also failed to affect the size 
of vMIA-expressing cells (Fig. 3 B). Transient transfection of 
vMIA imposed a cell-size reduction accompanied by a transition 
from a fi  lamentous to a punctate mitochondrial morphology in 
both HCT116
Bax+/− cells, which express Bax, and HCT116
Bax−/− 
cells, in which Bax was removed (Fig. 3, C and D). Altogether, 
these data provide strong evidence that the morphological effects 
of vMIA are independent from its apoptosis-inhibitory, Bax-
 mediated  function.
Actin polymerization and migration 
properties of vMIA-expressing cells
Both control and vMIA-expressing HeLa cells were enlarged 
when plated on either collagen type I– or fi  bronectin-coated 
  tissue plates, which increase adhesion to the culture substratum, 
but the difference in size between the cell types persisted 
(Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200604069/DC1), pointing to an intrinsic metabolic alteration 
imposed by vMIA.
Actin rearrangements that occur during migration are 
mainly controlled by the Rho-GTPase family (Ridley, 2001; 
Raftopoulou and Hall, 2004). To check if these pathways were 
impaired in vMIA cells, we transfected HeLa cells with GFP-
coupled wild-type RhoA and Rac-GTPase or with mutant con-
stitutively activated GTPase Rho- and Rac-Q. The distribution 
of actin was not infl  uenced by Rho-WT or Rac-WT, neither in 
control nor in vMIA-expressing cells (Fig. S4 A, available at 
http://www.jcb.org/cgi/content/full/jcb.200604069/DC1). This 
demonstrated that the vMIA-induced defect in actin polymer-
ization (and hence in migration) was not secondary to a defect in 
Rho-GTPase function. The percentage of cells showing  enhanced 
stress fi  ber polymerization in response to Rho-Q or increased 
cortex actin polymerization and cell surface adhesion in 
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cells (Fig. S4 B). Nonetheless, in qualitative terms, stress fi  bers 
were less numerous in vMIA cells than in Neo cells transfected 
with Rho-Q. Moreover, cortex actin was less polymerized and 
cell surface adhesion was comparatively reduced in vMIA cells 
transfected with Rac-Q (Fig. S4 B). Thus, the Rho-GTPase–
  induced actin polymerization was functional in HeLa vMIA 
cells, although at a reduced level. No defect in Rho-GTP could 
be measured in HeLa vMIA cells (Fig. S4 C). Activation of inte-
grins by extracellular matrix components, such as fi  bronectin or 
collagen, is a prominent migration inducer upstream of Rho-
GTPase proteins (Parsons et al., 2000; DeMali et al., 2003). 
Both fi  bronectin and collagen type I improved cortex actin poly-
merization and lamellipod extension in Neo and vMIA HeLa 
cells; they also enhanced focal adhesions, as assessed by the re-
localization and activating phosphorylation (Y397) of FAK (Fig. 
S4 D). However, we again noticed that lamellipod extension and 
cortex actin repolymerization induced by collagen type I or 
 fi bronectin was less pronounced in vMIA than in Neo HeLa 
cells. These experiments suggested that signaling pathways con-
trolling actin polymerization and migration were functional in 
vMIA HeLa cells, although these cells showed a reduced, de-
layed, and incomplete actin polymerization. Inhibition of actin 
disassembly with jasplakinolide completely restored stress fi  ber 
polymerization and the adherence surface of vMIA-expressing 
HeLa cells (Fig. S4 E), indicating that vMIA had no direct cata-
bolic effect on actin.
vMIA-mediated inhibition of mitochondrial 
ATP generation
Because vMIA-expressing cells exhibited a modifi  ed mitochon-
drial morphology, we tested whether oxidative phosphorylation 
would be compromised in these cells. No obvious changes in the 
Figure 1.  Mitochondrial morphological changes in cells expressing vMIA. (A) Immunoﬂ  uorescence stainings. The expression and localization of vMIA were 
analyzed by costaining of the Myc tag of vMIA and the core 2 subunit of the complex III on HeLa and NIH3T3 cells stably expressing vMIA (HeLa vMIA 
and NIH vMIA), as well as control cells (HeLa Neo and NIH Co). (B) Transmission electron microscopy of mitochondrion-rich areas from the indicated cell 
lines. Note the rounding and the disorganization of cristae in vMIA-expressing mitochondria. (C) Quantiﬁ  cation of mitochondrial mass by staining with 
  MitoTracker green. After staining, cells were subjected to ﬂ  ow cytometric analyses. (D) Immunoblotting of respiratory chain subunits. Lysates from the different 
cell lines were subjected to the immunochemical quantitation of the indicated proteins. GAPDH and actin were probed to control for equal loading.JCB • VOLUME 174 • NUMBER 7 • 2006  988
composition of respiratory chain complexes of HeLa cells could 
be detected by two-dimensional (native blue vs. SDS-PAGE) 
electrophoresis (Fig. S5, available at http://www.jcb.org/cgi/
content/full/jcb.200604069/DC1). Polarographic measurements 
of mitochondrial oxygen consumption indicated that ADP was 
unable to stimulate the respiratory activity of mitochondria from 
vMIA-expressing cells. Subsequent blockade of the F1F0ATP 
synthase by oligomycin only poorly decreased oxygen uptake 
in vMIA-expressing cells (respiratory control [RC] = 1.3), as 
compared with control (RC = 3.2). The decreased phosphory-
lating ability of the vMIA-expressing cells was further indicated 
by the similar effect of the uncoupler CCCP, functionally shunt-
ing the F1F0ATP synthase on both cell types (RC = 3.3 and 3.4 
for vMIA-expressing and control cells, respectively; Fig. 4 A). 
This result suggested that vMIA compromises the function of 
the ATP synthasome. The ATP synthasome is a multiprotein en-
semble composed of complex V (F1F0ATP synthase), ANT, and 
phosphate inorganic carrier (PiC; Chen et al., 2004). No differ-
ence in the abundance of the α-subunit of the F1F0ATP synthase 
was found between vMIA-expressing and control cells, as deter-
mined by immunoblotting. Moreover, vMIA-expressing cells 
and control cells possess a similar F1F0ATP synthase activity, 
Figure 2.  Effect of vMIA on cell size and the actin cytoskeleton. (A) Cell size of vMIA-expressing HeLa and NIH cells compared with control cells was deter-
mined by cytoﬂ  uorometric analyses of the FSC. (B) Plasma membrane surface of vMIA-expressing cells. The binding of the green ﬂ  uorescent dye PKH2-GL 
to the lipids of the cytoplasmic membrane was measured by cytoﬂ  uorometry and the mean channel was plotted. n = 4. Asterisks represent P = 0.05, t test. 
(C) Surface of adherence of vMIA-expressing cells. Cells were stained with CellTracker green, photographed, and subjected to morphometric analyses of 
the mean surface of adhesion. n = 2,200 cells. (D) Actin cytoskeleton in vMIA-expressing cells. Control or vMIA-expressing HeLa and NIH cells were 
stained with phalloidin–Alexa Fluor 568 and Hoechst 33342 to visualize actin and chromatin, respectively. Note the absence of stress ﬁ  bers and the dimi-
nution of the actin cortex induced by vMIA. (E) Adhesion kinetics of vMIA-expressing cells. Cells were trypsinized and allowed to adhere during the indi-
cated period of time, and the percentage of adherent cells was determined by phase-contrast microscopy. n = 3. (F) Inﬂ  uence of vMIA on wound healing. 
The cell monolayer was wounded, and the movement of cells ﬁ  lling the gap was recorded at different times. The mean wound size is plotted. n = 4. 
Error bars represent the mean ± the SD.THE EFFECT OF VMIA ON BIOENERGETICS • PONCET ET AL. 989
as determined by spectrophotometric assays (Fig. 4 B). vMIA 
  reportedly interacts with mitochondria, particularly with ANT 
(Goldmacher et al., 1999; Vieira et al., 2001). Hence, we deter-
mined the ANT activity on isolated mitochondria in an in vitro 
assay that does not yield information on the absolute ANT activ-
ities, yet allows for the comparison between control and vMIA-
expressing cells. vMIA did not compromise the relative ANT 
activity and rather enhances the uptake of ADP into isolated 
  mitochondria (by a factor of  2), which can be explained by an 
increased abundance of ANT protein (Fig. 4 C). Inhibition of 
the adenylate kinase, using P1, P5-Di (adenosine-5′-) pentaphos-
phate or that of the F0 part of the ATP synthase by oligomycin, 
did not abolish the difference in the ADP/ATP exchange rate 
  between mitochondria from control and vMIA-expressing cells, 
whereas carboxyatractyloside totally inhibited the ANT activity 
and the ATP effl  ux measured (unpublished data). The data ob-
tained on ANT activity of isolated mitochondria (Fig. 4 C) were 
backed up by experiments performed on intact cells (Fig. 4 D). 
Real-time measurements of the intramatrix ATP levels using 
permeabilized cells transfected with a mitochondrion-targeted 
luci  ferase (Jouaville et al., 1999) revealed that the baseline 
  matrix ATP levels were reduced in vMIA-expressing cells, sug-
gesting defective mitochondrial ATP synthesis. The rate of im-
port of external ATP into the mitochondrial matrix was enhanced 
in vMIA-expressing cells as compared with control cells (Fig. 4 D). 
Thus, ANT activity was enhanced by vMIA, much in the way 
that this has been observed for Bcl-2 overexpression, which also 
stimulates ANT activity (Belzacq et al., 2003).
Next, we investigated the vMIA effect on the third com-
ponent of the ATP synthasome, the mitochondrial phosphate 
carrier. vMIA had no effect on the abundance of the phosphate 
carrier (Fig. 4 E). However, vMIA reduced the uptake of 
[
33P]phosphate into isolated mitochondria by  80%, compared 
with control mitochondria (Fig. 4 E), as determined by an 
in vitro assay. This observation was confi  rmed in permeabilized 
cells that were initially kept in a phosphate-depleted medium, in 
which ATP synthesis (as detected by matrix- targeted luciferase) 
was stimulated by the addition of increasing amounts of in-
organic phosphate (Fig. 4 F). The phosphate-stimulated ATP 
  generation was reduced in vMIA-  expressing cells. Altogether, 
these data support the notion that vMIA inhibits mitochondrial 
ATP production, correlating with a decreased activity of the 
phosphate carrier.
Correlating with the defect in oxidative phosphorylation 
induced by vMIA (Fig. 4), vMIA-expressing cells exhibited 
a lower steady-state ATP level, which was  70% of that in 
control cells (Fig. 5 A). The ATP levels in cells transfected with 
a vMIA mutant lacking the mitochondrion-targeting domain 
Figure 3.  vMIA-induced morphological changes 
in Bax-negative cells. (A) Effect of the Bax 
knockdown. HeLa Neo or HeLa vMIA cells 
were transfected with a control siRNA or either 
of two Bax-speciﬁ   c siRNAs, and the down-
  regulation of Bax was conﬁ  rmed by immunob-
lotting 3 d after transfection. Bax-depleted or 
control cells were subjected to FACS analysis 
and the mean size (FSC) was determined. 
n = 3. Asterisks represent P > 0.05, t test. 
(B) Effect of the Bak knockdown. HeLa vMIA 
cells were depleted from Bak with two different 
siRNAs, and the impact of this manipulation 
was determined on cell size 2 d after transfection. 
(C) Impact of vMIA on Bax-deﬁ  cient HCT116 
cells. HCT116 
Bax+/− and 
Bax−/− cells were 
transfected either with vMIA or Myc control 
vectors, and cell size was measured by FACS 
analysis. n = 3. (D) vMIA-induced fragmenta-
tion of the mitochondrial network in the ab-
sence of Bax. The mitochondrial fragmentation 
was determined by immunoﬂ  uorescence  mi-
croscopy after immunostaining of the vMIA 
Myc tag and the core 2 subunit of complex III 
in HCT116 
Bax−/− cells. Error bars represent 
the mean ± the SD.JCB • VOLUME 174 • NUMBER 7 • 2006  990
Figure 4.  Effect of vMIA on mitochondrial respiration. (A) Respiratory control in BJAB cells transfected either with vMIA or the Myc control vector (Myc). 
Cells were permeabilized, placed in an oxygen electrode, and subjected to the sequential addition of the indicated agents. Note that ADP does not 
  stimulate the oxygen consumption of vMIA-expressing cells, although it does so in control cells. n = 3. Similar data were obtained in HeLa cells 
(not   depicted). (B) F1F0ATP synthase activity in vMIA-expressing cells. The ATP synthase activity of isolated mitochondria was determined by spectrophotometry, 
and the abundance of the α subunit was determined by immunoblotting (top). Error bars represent the mean ± the SD. (C) ANT activity in vMIA-
  expressing mitochondria. Increasing amounts of ADP were added to isolated mitochondria of control and vMIA cells, and the translocase activity of ANT 
was evaluated as proportional to the NADP
+ reduction measured by luminescence assay. Data were ﬁ  tted with the Michaelis–Menten equation under 
Kaleidagraph software (Synergy Software). (top) Immunoblot determinations of ANT protein levels. (D) Resting mitochondrial ATP levels and ANT activity 
in HeLa cells. mtLuc-transfected cells were selectively permeabilized with 25 μM digitonin in an intracellular-like solution that leaves mitochondrial mem-
branes intact. The luciferase activity was monitored to measure the concentration of ATP in the mitochondrial matrix. Before each measurement, cells 
were pretreated with 5 μM oligomycin for 10 min. The mean ± the SEM of 25 traces are shown in control (black) and vMIA stably transfected (gray) 
HeLa cells. The ATP/ADP exchange activity of ANT is represented by the kinetics of ATP level after the addition of 500 μM ATP. (E) Phosphate uptake in THE EFFECT OF VMIA ON BIOENERGETICS • PONCET ET AL. 991
(∆23-34) (Hayajneh et al., 2001) were similar to that of control 
cells (Fig. 5 B). Cells expressing vMIA produced more lactate 
than control cells, indicating that the defect in mitochondrial 
ATP generation was partially compensated for by an increased 
anaerobic glycolysis (Fig. 5 C). The partial decrease in ATP in-
duced by vMIA, however, was not suffi  cient to cause a manifest 
activation of the AMP kinase (AMPK)–mammalian target of 
rapamycin (mTOR)–p70
S6K kinase pathway, as suggested by 
the absence of an increased phosphorylation of AMPK and 
p70
S6K kinase in vMIA-expressing cells (Fig. 5 D).
Morphological alterations associated 
with a cellular ATP defect and a defect 
in the mitochondrial phosphate carrier
Having established that vMIA-expressing cells had a reduced 
capacity to generate ATP, we then evaluated the impact of a par-
tial ATP defect on cellular morphology. Exposure of HeLa Neo 
cells (not depicted) or NIH3T3 control cells to 10 nM oligomycin, 
which inhibits mitochondrial ATP generation, led to an  30% 
reduction of the intracellular ATP concentration and to a de-
crease in mean cell size (Fig. 6 A), accompanied by reduced 
  actin polymerization (Fig. 6 B) and a diminished wound healing 
capacity (Fig. 6 C) similar to that found in vMIA-expressing 
cells (Fig. 2). Inhibition of the respiratory chain complexes I and II 
by rotenone and TTFA, respectively, also reduced ATP levels and 
cell size (Fig. 6 D). Thus, expression of vMIA and exposure of 
cells to inhibitors of ATP production led to similar morphologi-
cal changes, suggesting that the effects of vMIA on cellular mor-
phology stem from the vMIA-induced changes in mitochondrial 
energetics, especially from reduced ATP levels. To formally 
prove that the defect in the mitochondrial carrier induced by 
vMIA is responsible for the cytopathic effect, we knocked down 
the phosphate carrier with two different siRNAs (Fig. 6 E), show-
ing that this manipulation reduced the size of control HeLa cells, 
yet had no signifi  cant effect on the size of HeLa vMIA cells (Fig. 
6 F). These data suggest that the effect of vMIA on cell size is 
secondary to its inhibitory effect on the phosphate carrier.
Cytopathic effects of vMIA 
during CMV infection
To examine the effects of vMIA in the context of CMV infec-
tion, we infected human fi  broblasts, which are a cell type per-
missive for CMV, with either a CMV virus that encodes 
functional vMIA or with a vMIA-defi  cient CMV strain. To pre-
vent apoptosis, we used MRC5
E1B19k fi  broblasts  expressing 
E1B19K, which is a strong cell-death suppressor that has pre-
viously been shown to suppress apoptosis induced by vMIA-
defi   cient CMV (Reboredo et al., 2004). MRC5
E1B19k cells 
infected by CMV exhibited a marked rounding-up  24 h after 
infection. This ECE coincided with the onset of strong vMIA 
expression, as detected by immunofl  uorescence (Fig. 7, B and C). 
In contrast, vMIA-defi  cient CMV, while infecting the cell 
  productively (not depicted), failed to induce ECE, indicating 
that the observed morphological alteration is truly attributable 
to vMIA expression (Fig. 7, A–C). In addition to its effects on 
the global cellular morphology, the expression of vMIA in cells 
infected with CMV caused a rapid (10 h after infection) frag-
mentation of the mitochondrial network, from a fi  lamentous to 
a punctuate pattern, in accordance with previously published 
data (McCormick et al., 2003). To determine the temporal order 
between the mitochondrial and the cellular effects of vMIA, 
we performed confocal microscopy of the vMIA expression in 
CMV-infected cells, followed by three-dimensional reconstruction 
of the staining patterns of vMIA and actin. At a fi  rst step, vMIA 
Figure 5.  Metabolic effects of vMIA. (A) Basic cellular 
ATP levels in control and vMIA-expressing cell lines. 
100% values are set for controls. Error bars represent 
the mean ± the SD. n = 6. (B) Basic cellular ATP levels 
in Myc (control), vMIA wt, and vMIA∆23-34–transiently 
expressing cells. 100% values are set for controls. 
  Representative results are presented. (C) Glucose (left) 
and lactate concentrations (right) in the medium of 
vMIA-expressing HeLa cells as compared with normal 
controls. The measurements were performed in three 
separate experiments. (D) Effects of vMIA on the phos-
phorylation of AMPK and p70
S6K. Immunoblots were 
probed with antibodies recognizing the indicated phos-
phoproteins or the proteins as such.
vMIA-expressing mitochondria compared with control mitochondria, as determined in Materials and methods. Immunoblots show the determination of 
PiC protein level. (F) Kinetics of phosphate uptake into mitochondria from vMIA-expressing and control HeLa cells. Mitochondrial ATP levels were mea-
sured as in D. To ensure maximal activity of the F1F0ATP synthase, 1 mM ADP and 100 μM ATP were used in the intracellular buffer. Representative traces 
from three separate experiments are shown.JCB • VOLUME 174 • NUMBER 7 • 2006  992
was   expressed in mitochondria without any major morpho-
logical effect. At a second step, vMIA-decorated mitochondria 
fragmented, while cells conserved a normal shape and a normal 
actin cytoskeleton. At a fi  nal stage, the fragmented mitochon-
drial network collapsed around the nucleus when cells rounded 
up (Fig. 7 D). This indicates that the mitochondrial change pre-
cedes cytoskeleton alterations and rounding of the cells. The LCE 
of CMV, nuclear and cytoplasmic granulation, and enlargement 
Figure 6.  Effect of ATP depletion on cell size and the actin cytoskeleton. (A) Impact of ATP depletion on cell size. ATP levels and cell size were determined 
after 48-h treatment of NIH control cells with increasing doses of oligomycin. Similar results were obtained for HeLa cells (not depicted). (B) Impact of ATP 
depletion on the actin cytoskeleton. NIH control cells were cultured in the absence or presence of 10 nM oligomycin for 2 d, and then stained to visualize 
actin and chromatin. Note the reduction of stress ﬁ  bers, cell size, and adhesion surface. (C) Impact of ATP on wound healing. The NIH control monolayer 
was wounded, and the size of the gap was evaluated at different times. n = 3. (D) Impact of complex I and II inhibition on cell size. Control NIH cells were 
treated with 10 nM rotenone or 1 mM TTFA for 48 h, and the cellular ATP level and cell size were measured. (E and F) Effect of the depletion of the mito-
chondrial PiC on cell size. The phosphate carrier was depleted using two distinct siRNAs, and the abundance of the mRNA transcript and the protein levels 
(E) or cell size (F) were assessed 2 d after transfection. Asterisks indicate signiﬁ  cant effects on cell size (n = 3) in phosphate carrier–depleted cells, as com-
pared with control transfectants. Error bars represent the mean ± the SD.THE EFFECT OF VMIA ON BIOENERGETICS • PONCET ET AL. 993
of infected cells, associated with a complete loss of phalloidin-
detectable actin polymers, was observed 5 d after   infection (Fig. 
7 E). vMIA was required for the manifestation of LCE because 
infection with a vMIA-defi  cient CMV strain failed to induce 
granulation and actin depolymerization (Fig. 7 F). Altogether, 
these data demonstrated a major contribution of vMIA to the 
pathognomonic cytopathic effects of CMV.
Discussion
vMIA is a CMV-derived protein endowed with the capacity of 
disabling apoptosis through inhibiting Bax-mediated MOMP. 
We unraveled a hitherto unexpected effect of vMIA that affects 
mitochondrial bioenergetics and, hence, multiple cellular func-
tions, including shape, size, adhesion, and mobility.
vMIA possesses some functional similarities with Bcl-2   
(or Bcl-XL), yet exhibits important differences in respect to this 
family of endogenous apoptosis inhibitors. Both vMIA and Bcl-2 
act on mitochondria to inhibit MOMP (Susin et al., 1996; Kluck 
et al., 1997; Yang et al., 1997) and diversion of these proteins to 
other subcellular localization largely reduces their antiapoptotic 
potential (Zhu et al., 1996; Goldmacher et al., 1999; Hayajneh 
et al., 2001). Both vMIA and Bcl-2 reportedly interact with ANT 
(Marzo et al., 1998; Goldmacher et al., 1999), and both enhance 
the antiporter activity of ANT (Belzacq et al., 2003; this study). 
This correlates with the observation that Bcl-2 and Bcl-XL in-
hibit the pore-forming function of ANT, while enhancing ATP 
  exchange on the membranes of isolated mitochondria (Vander 
Heiden et al., 1999, 2001; Belzacq et al., 2003). Similarly, the 
antiapoptotic function of vMIA has been correlated with a re-
duced permeabilization of mitochondrial membranes, through an 
effect on either ANT (Belzacq et al., 2001; Goldmacher et al., 
1999) or Bax (Arnoult et al., 2004; Poncet et al., 2004). In 
contrast to Bcl-2, vMIA partially reduces cellular ATP levels. 
Figure 7.  vMIA-dependent cytopathic effects 
of CMV. (A–D) ECE of CMV-encoded vMIA. 
  Human MRC5
E1B19K ﬁ   broblasts were infected 
with wild-type (WT) CMV or a vMIA-deﬁ  cient 
CMV (∆vMIA) for the indicated period (28 h in 
A, B, and D), followed by staining of actin 
(A, B, and D) and the viral proteins IEA (A) or 
vMIA (B and D). The percentage of cells exhib-
iting ECE was determined among the cells 
  expressing IEA or vMIA (C). Confocal immuno-
ﬂ   uorescence (YX/planar and XZ/vertical 
views) of wild-type CMV-infected cells was per-
formed, and the three stages of vMIA expres-
sion are shown in D; without mitochondrial 
fragmentation and cell rounding (step 1), with 
mitochondrial fragmentation and without 
rounding (step 2), and with fragmentation and 
rounding (step 3), representing  10,  2, and 
 88% of the cells, respectively. (E and F) LCE 
of wild-type (WT) and vMIA-deﬁ  cient (∆vMIA) 
CMV. Human MRC5
E1B19K ﬁ  broblasts  were 
  infected with WT or ∆vMIA CMV for the indi-
cated period (5 d in E; 4–7 d in F), followed by 
staining of actin and the viral protein EA. 
  Arrows indicate cells with a marked cytopathic 
effect, namely, granulation and near-to-completed 
disappearance of the actin cytoskeleton (E). 
The percentage of cells expressing EA was 
quantiﬁ  ed and the percentage of cells exhibit-
ing LCE was determined among the cells ex-
pressing EA (F). Typical results representative 
of three independent experiments are shown. 
Error bars represent the mean ± the SD.JCB • VOLUME 174 • NUMBER 7 • 2006  994
Moreover, Bcl-2 has no effects on mitochondrial dynamics and 
cell size, whereas vMIA causes fragmentation of the mitochondrial 
network and cell size reduction. Thus, paradoxically, vMIA be-
haves like Bax or t-Bid, which can fragment mitochondria during 
apoptosis induction (Nechushtan et al., 2001; Karbowski et al., 
2002; Lucken-Ardjomande and Martinou, 2005; Perfettini et al., 
2005). Nonetheless, the effect of vMIA on cellular bioenergetics 
is independent of its interaction with Bax because Bax-negative 
cells still manifest the mitochondrial fragmentation and bioener-
getic effects induced by vMIA. Importantly, vMIA compromises 
the function of the phosphate carrier, which is the mitochondrial 
inner membrane protein that exchanges phosphate anions by hy-
droxyl anions and that oligomerizes with ANT (and the F1F0ATP 
synthase) within the so-called ATP synthasome. This structure 
generates ATP within the matrix, while guaranteeing for its export 
(which is limited by the import of its precursors, i.e., ADP 
and inorganic phosphate). Thus, a strong inhibition of phosphate 
carrier activity by vMIA can limit the generation of ATP in the 
matrix and cause a bioenergetic defi  ciency in the entire cell. How 
vMIA (which is located in the mitochondrial outer membrane) 
affects the function of the phosphate carrier (in the inner mito-
chondrial membrane) remains a conundrum. However, it has 
been found that proteins that are located in the inner membrane 
can interact with outer membrane proteins within contact sites, 
and allosteric effects across the two membranes have been 
 documented (Crompton, 2003; Halestrap and Brennerb, 2003; 
  Machida et al., 2006).
One plausible explanation of the fi  ndings obtained in this 
paper is portrayed in the following scenario. Upon CMV infec-
tion, the UL37 exon 1 is transcribed and translated into vMIA 
protein, which is imported into mitochondria, where it interacts 
with the ATP synthasome, reducing the enzymatic activity of 
the phosphate carrier. This ultimately causes a reduction in 
  mitochondrial ATP production and, hence, whole ATP levels. By 
analogy with other inhibitors of mitochondrial respiration that 
induce reversible mitochondrial fragmentation without apopto-
sis induction (Legros et al., 2002; Ishihara et al., 2003), vMIA 
induces mitochondrial fi  ssion. On theoretical grounds, the dis-
ruption of the mitochondrial network could be caused by either 
ATP depletion or the effects on mitochondrial proteins. Thus, 
reduced ATP levels can inhibit mitofusin-1–dependent fusion 
without   affecting Drp1-dependent fi  ssion, causing mitochon-
drial fragmentation as the net result (Legros et al., 2002). 
Moreover, the antiretroviral drug nelfi  navir, which affects ANT 
structure (Weaver et al., 2005), can induce mitochondrial frag-
mentation without reducing ATP levels (Perfettini et al., 2005; 
Roumier et al., 2005). Thus, it is not clear whether the vMIA-
induced ATP depletion or the vMIA interaction with the ATP 
synthasome accounts for the alteration of mitochondrial 
  dynamics. Shortly after mitochondrial fi  ssion, cells manifest 
rounding-up and accumulate a series of alterations that are 
similarly induced by vMIA expression or ATP depletion, 
namely a reduction in cell size, adhesion, and mobility. These 
changes correlate with a depolymerization of stress fi  bers and 
a reduced actin cortex, two changes that are not secondary to 
  alterations in Rho or Rac signaling. Although ATP and GTP 
levels may be expected to correlate (Dagher,  2000), no detectable 
defect in Rho-GTP levels was induced by vMIA. Previous 
studies have unraveled the deleterious effects of ATP depletion 
on the actin cytoskeleton, resulting in lamellipod retraction, 
stress fi  ber collapse, and ventral F-actin aggregation, e.g., in 
conditions of ischemia (Ganote and Armstrong, 1993; Shelden 
et al., 2002; Atkinson et al., 2004). Hence, the effects induced 
by vMIA on the cytoskeleton are likely to be fully explained by 
ATP depletion.
At fi  rst glance, it appears counterintuitive that a virus might 
be “interested” in reducing ATP levels, which might compro-
mise cellular functions and, hence, reduce viral replication. 
  Indeed, herpesviridae other than CMV encode apoptosis-inhibitory 
proteins with a marked homology to Bcl-2. This applies, for 
  example, to two nononcogenic herpesviruses (Herpesvirus Saimiri 
and Herpesvirus 68), as well as to two oncogenic viruses, 
namely, Kaposi’s sarcoma associates herpesvirus and Epstein 
Barr virus (Cuconati and White, 2002; Hardwick and Bellows, 
2003; Boya et al., 2004). Transfection of the two Epstein Barr 
virus Bcl-2 homologues, BALF or BHRF1, has no measurable 
effect on mitochondrial or cellular morphology (unpublished 
data), indicating that they act like endogenous Bcl-2. As a mat-
ter of speculation, a partial reduction of ATP levels, by  30%, 
might be “useful” for CMV. As a possibility, actin depolymer-
ization might facilitate the anterograde and retrograde traffi  c of 
viral particles and products throughout the CMV life cycle, as 
has been suggested previously (Jones et al., 1986; Cudmore 
and Reckmann, 1997; Ploubidou and Way, 2001; Dohner and 
  Sodeik, 2005). Moreover, reduced adhesion or migration of 
CMV-infected cells might participate in the theratogenic effects 
of CMV, e.g., on the fetal brain (Shinmura et al., 1997).
Among the β-herpesviridae, CMV is characterized by a 
long life cycle (4–5 d) and a peculiar cytopathic effect, which is 
observable on many different CMV-infectable cell types (Kowalik 
et al., 1994; Warren et al., 1994). This characteristic cytopathic 
 effect shaped the name of the virus. The data reported in this study 
provide a molecular explanation for the cytopathic effect of CMV, 
which can be attributed to the expression of one single viral 
 protein,  vMIA.
Materials and methods
Cell culture, transfection, CMV infection, and treatment
HeLa and BJAB vMIA-expressing cells were previously described 
(Goldmacher et al., 1999). NIH3T3 cells were stably transfected with 
pLncx/vMIAmyc, coding for vMIA-Myc (provided by F. Subra, Ecole 
  Normale Supérieure, Cachan, France). MRC5 human ﬁ  broblasts stably 
expressing E1B19K protein (MRC5
E1B19K) were infected with vMIA-deﬁ  -
cient CMV (CMV
∆vMIA) or its parental strain, AD169varATCC (CMV WT; 
  Reboredo et al., 2004). HCT116
Bax−/− cells were provided by B. Vogelstein 
(Johns Hopkins University, Baltimore, MD; Zhang et al., 2000). MRC5, 
HeLa, BJAB, and HCT116 were cultured as previously described 
(Poncet et al., 2004). NIH3T3 cells were cultured in DME supplemented 
with 10% newborn calf serum. To knock down Bax, Bak, or PiC expres-
sion, two siRNAs were used (hBax-384 for Bax1, hBax-208 for Bax2, 
hBak01-258 for Bak1, [Perfettini et al., 2004] Qiagen hp_Bak_1_5 for 
Bak2; and sense strands C  U  G  G  C  G  C  A  C  A  U  C  A  C  U  A  U  A  U   and C  C  A  G  G  U-
U  A  U  G  C  C  A  A  C  A  C  U  U   for PiC1 and PiC2, respectively). As a control, 
siRNA luciferase (Proligo, siRNA luc) was used. 0.5 μl Oligofectamine 
(Invitrogen) and 30 pmol siRNA were added to a 24-well plate. Plasmid 
transfections were performed in a 6-well plates using Lipofectamine 
(Invitrogen) at a ratio of 3 μg Lipofectamine for 2 μg plasmid. NIH3T3 
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Cytoﬂ  uorometry and microscopy
Cells were incubated for 15 min at 37°C with 150 nM MitoTracker green 
(Invitrogen). The cell size was quantiﬁ  ed as the forward scatter channel 
(FSC). Plasma membranes were labeled with the PKH2 Green Fluorescent 
Cell Linker kit (Sigma-Aldrich). Immunoﬂ  uorescence experiments were per-
formed as previously described (Castedo et al., 2002). vMIA Myc-tag, 
actin ﬁ  laments, and DNA were visualized using Myc-FITC (Abcam), Alexa 
Fluor 568 phalloidin (Invitrogen), and Hoechst 33342 (Invitrogen). The 
primary antibodies used were as follows: vMIA (Goldmacher et al., 
1999), immediate early antigen (IEA), early antigen (EA; Argene), and 
complex III core 2 (Invitrogen). Secondary Alexa Fluor–coupled anti-
bodies were obtained from Invitrogen. In most experiments, a Leica 
DMIR2 inverted ﬂ  uorescence microscope (camera DFC300FX, acquisition 
software Leica FW4000) was used. For adhesion assay, cells were tryp-
sinized and seeded on Nunc culture dishes. Alternatively, cells were 
grown to conﬂ  uence and the monolayer was wounded by scratching with 
a pipette tip. Photographs were taken with visible light at 10×. To calcu-
late the cell surface area, cells cultured on polystyrene dishes were   labeled 
for 40 min with 1 μM CellTracker green (Invitrogen) and washed, and 
then photographs were taken in 10 areas at 10× (LSM510 confocal 
  microscope; Carl Zeiss MicroImaging, Inc; and ImageJ software;   National 
Institutes of Health). Cells infected with CMV were examined with a 
LSM510, using LSM Image Browser (Carl Zeiss MicroImaging, Inc.. Trans-
mission electron microscopy was performed as previously described 
(Boya et al., 2005).
Bioenergetic methods
ATP was measured with the bioluminescence assay kit HS-II (Roche). 
  Polarographic studies performed on BJAB cells were performed as previ-
ously described (Rustin et al., 1994). The RC was calculated by dividing 
oxygen consumption before and after addition of ADP/ATP. The oligomycin-
sensitive F1F0ATP synthase activity was measured using the spectrophoto-
metric-coupled assay with pyruvate kinase and lactic dehydrogenase 
(Rustin et al., 1994). To measure ANT activity in vitro, mitochondria were 
isolated from Neo and vMIA HeLa cells by differential centrifugation in 
0.3 M sucrose buffer at 4°C. The ADP/ATP exchange rates of the two 
types of mitochondria were concomitantly evaluated on the equivalent of 
75-μg mitochondrial proteins in a 96-multiwell plate. ATP efﬂ  ux induced 
by externally added ADP was monitored by following NADP+ reduction, 
as previously described (Passarella et al., 1988). This assay was vali-
dated for microtiter plate format analysis and found to produce results 
similar to the radiolabeled-ATP–based assay (Belzacq et al., 2003). For 
determination of phosphate carrier activity (Palmieri and Klingenberg, 
1979), mitochondria from HeLa cells were isolated using a mitochon-
drial isolation kit (Pierce Chemical, Co.). 1 mM [
33P]phosphate was 
added to 60 μg mitochondria suspended in 250 mM sucrose, 1 mM 
EDTA, and 10 mM Tris-HCl, pH 7.4, in a ﬁ  nal volume of 110 μl at 25°C. 
The reaction was terminated after 5 min by addition of 1 mM mersalyl 
(Sigma-Aldrich). D-Glucose and L-Lactic acid amounts in cell culture me-
dia were calculated by the UV method, with enzymatic kits (Boehringer 
Mannheim/R-Biopharm). To measure the mitochondrial ATP levels in 
vivo, HeLa cells seeded on glass coverslips were transfected with 3 μg 
mitochondrially targeted luciferase (Jouaville et al., 1999). 36 h later, 
cells were transferred to a custom-built luminometer perfusion chamber 
(Rizzuto et al., 1998). The plasma membrane was selectively permeabi-
lized with 25 μM digitonin for 1 min, and cells were suspended in an 
  intracellular-like buffer (130 mM KCl, 10 mM NaCl, 1 mM MgSO4, 5 mM 
succinate, 0.5 mM K2HPO4, 20 mM Hepes, pH 7.0, 1 mM EGTA, and 
130 μM CaCl2, giving a free [Ca
2+] of 100 nM) at 37°C. Before addi-
tion of 20 μM luciferin, ATP, and ADP, cells were treated for 10 min with 
5 μM oligomycin. Traces were normalized to the minimal and maximal 
luminescence levels obtained in the 500 μM ADP/no ATP and no 
ADP/500 μM ATP solutions, respectively. To measure phosphate depen-
dency, cells were perfused consecutively with 0, 0.1, 0.5, and 1 mM 
H2PO4
− in conditions of maximal activity of the F1F0 ATP synthase 
  (obtained by addition of 1 mM ADP and 100 μM ATP).
Immunoblotting
Cells were lysed in 0.1% SDS-PBS buffer and spun for 5 min at 15,000 g. 
25 μg total protein were separated by SDS-PAGE. The primary antibodies 
used were as follows: Myc 9E10 (Santa Cruz Biotechnology, Inc.), Bax 
N-ter (Millipore), GAPDH, actin (CHEMICON International, Inc.), and PiC 
(Fiermonte et al., 1998). All antibodies speciﬁ  c for OXPHOS subunits were 
obtained from Invitrogen. Antibodies for mTOR, AMPK, and p70S6K were 
purchased from Cell Signaling Technology. Secondary HRP conjugated 
  antibodies were obtained from Southern Biotechnologies.
Online supplemental material
Fig. S1 shows the cell cycle independence of cell size reduction induced 
by vMIA. Fig. S2 shows cell type–speciﬁ  c apoptosis inhibition by vMIA. 
Fig. S3 shows the effect of the cell culture substrates on cell size. Fig. S4 
shows the effects of Rho and Rac GTPases (provided by C. Lamaze, Curie 
Institute, Paris, France), cell culture substrates on the actin cytoskeleton, 
and focal adhesion. Fig. S5 shows two-dimensional gel electrophoresis 
of respiratory chain complexes from control and vMIA-expressing 
  mitochondria. Online supplemental material is available at http://www.
jcb.org/cgi/content/full/jcb.200604069/DC1.
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